Sunday, January 11, 2015 1:10:20 PM
#1 - 29 per cent gain in one day is NOT overpumped if the news has substance. This isn't fluff - it's 60 million upfront and up to 350 million if it reaches various milestones.
#2 - Shingles vaccine alone with a 97 per cent effective rate will bring in huge revenue streams.
#3 - Several upgrades all at 10.00 or more coming in Friday. They all know how big of a deal this is.
#4 - You can expect more upgrades as this news digests. One upgrade came in when the company was at 4.91 on Friday and heavy buying took it all the way back up to 5.50 range immediately.
#5 - Afterhours, Jimmy Cramer is telling everyone this is the last chance to get in at these prices. He could not contain his excitement when he had CEO Garo on his show because he knows this is a blockbuster here.
#6 - Institutional investment coming in as this is over 5.00 range - just starting to build their positions. You can expect more money coming in very soon.
#7 - This is only the second day of the run - looking for 3 good days here.
#8 - This will be extremely volatile and is officially in play. There is quite a buzz here and you can expect runs throughout the day, both up and down but trending higher as more people believe in this as a long term investment and not a quick trade. I am looking at the 5.20 level as the floor but not quite sure how high this can or will go from here. I do believe this will eventually be much, much higher from here.
Recent AGEN News
- Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement • Business Wire • 05/01/2024 11:30:00 AM
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting • Business Wire • 04/24/2024 02:00:00 PM
- Agenus to Provide First Quarter 2024 Financial Report and Corporate Update • Business Wire • 04/23/2024 11:30:00 AM
- Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer • Business Wire • 04/12/2024 11:30:00 AM
- Agenus Announces Reverse Stock Split of Common Stock • Business Wire • 04/05/2024 08:30:00 PM
- Agenus Reports Fourth Quarter and Full Year 2023 Results • Business Wire • 03/14/2024 11:30:00 AM
- Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 • Business Wire • 03/06/2024 12:30:00 PM
- Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/05/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/29/2024 09:50:48 PM
- Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report • Business Wire • 02/29/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/26/2024 09:24:59 PM
- Agenus to Participate in Leerink Partners Global Biopharma Conference • Business Wire • 02/26/2024 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/15/2024 01:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 01:00:11 PM
- Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design • PR Newswire (US) • 02/15/2024 12:02:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:33:12 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 12:00:12 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:11:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 01:00:10 PM
- Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference • Business Wire • 01/31/2024 12:30:00 PM
- Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population • Business Wire • 01/22/2024 02:59:00 PM
- Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population • Business Wire • 01/22/2024 12:30:00 PM
- Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/05/2024 09:30:00 PM
- Agenus to Participate in B. Riley Healthcare Conference • Business Wire • 01/04/2024 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM